Last update 01 Nov 2024

Temmler Pharma GmbH & Co. KG

Subsidiary Company|
1917|
Germany
|
www.temmler.de

Overview

Basic Info

Introduction
Temmler Pharma GmbH & Co. KG is a pharmaceutical development and manufacturing company that operates as part of the Temmler Group of Companies. With its headquarters located in Marburg, Germany, the company has been in operation since 1917.

Tags

Congenital Disorders
Nervous System Diseases
Other Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases1
Top 5 Drug TypeCount
Small molecule drug1
Top 5 TargetCount
VMAT2(Synaptic vesicular amine transporter)1

Related

1
Drugs associated with Temmler Pharma GmbH & Co. KG
Tetrabenazine
Target
VMAT2
Mechanism
VMAT2 inhibitors
Active Org.
Alfresa Pharma Corp.Alfresa Pharma Corp. [+9]
Originator Org.
Hoffmann-La Roche Products Ltd.
Active Indication
Huntington Disease [+2]
Inactive Indication
Tourette Syndrome
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
AU
First Approval Date23 Aug 1991
100 Clinical Results associated with Temmler Pharma GmbH & Co. KG
Login to view more data
0 Patents (Medical) associated with Temmler Pharma GmbH & Co. KG
Login to view more data
1
News (Medical) associated with Temmler Pharma GmbH & Co. KG
21 Dec 2006
Astellas Pharma Inc. Transfers Three European Plants To Temmler Group, German Pharmaceutical Company
100 Deals associated with Temmler Pharma GmbH & Co. KG
Login to view more data
100 Translational Medicine associated with Temmler Pharma GmbH & Co. KG
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 25 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Approved
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Tetrabenazine
 ( VMAT2 )		Dyskinesia, Drug-Induced
More
Approved
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free